Discotrine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Discotrine

Discotrine is a prescription-only pharmaceutical preparation utilized in cardiovascular care. It is fundamentally defined by its active component, Nitroglycerin, and is classified within the group of Organic Nitrates and as a potent Vasodilator.

Property Description
Active ingredient Nitroglycerin (Glyceryl Trinitrate)
Form Sublingual Tablet, Oral Spray, Transdermal Patch
Pharmacological class Organic Nitrate, Vasodilator
General purpose Alleviates myocardial ischemia
Origin Synthetic compound

What Type of Medicine is Discotrine?

Discotrine is classified as a potent Vasodilator and an Anti-ischemic agent. This means its primary function is to widen blood vessels and improve the blood-oxygen balance in the heart muscle. As an essential cardiovascular medicine, it works directly on the muscular walls of blood vessels. The use of organic nitrates is associated with the reduction of cardiac oxygen demand. This conclusion confirms that the medicine primarily works by easing the effort required by the heart. Its use is clinically recognized for providing relief during typical episodes of exertion-related chest discomfort.

Discotrine’s Composition and Available Forms

The active ingredient in Discotrine is Nitroglycerin (Glyceryl Trinitrate), a synthetic compound used as a single-ingredient product (monotherapy). This medicine is available in several dosage forms, allowing for versatile administration depending on the required speed and duration of effect. Common forms include the sublingual tablet and lingual spray for rapid absorption, as well as the transdermal patch or ointment for extended, sustained-release delivery. Discotrine, unlike some generic formulations, may be distinguished by specific excipients designed to enhance the stability or absorption profile of the highly volatile Nitroglycerin molecule.

General Purpose: Why is Discotrine Used?

The general purpose of Discotrine is to reduce the workload on the heart by acting as a Nitric Oxide (NO) donor. This action causes significant venous dilation, thereby decreasing the volume of blood the heart must pump (reducing preload). By relieving this strain and promoting relaxation of the coronary arteries, Discotrine aims to alleviate the underlying oxygen deprivation, or myocardial ischemia, that causes acute chest discomfort. Nitroglycerin is utilized for its rapid onset of action in relieving symptoms of chest pain associated with this condition. The prompt onset of action makes this medicine suitable for providing fast relief when symptoms occur, such as during episodes of chronic stable angina.

Regulatory References

  1. WHO Essential Medicines List for Glyceryl trinitrate

What side effects are possible with Discotrine?

Discotrine: Possible Side Effects and Safety Information

The official safety profile of Discotrine, based on its active component Nitroglycerin, is formally documented by government regulatory agencies. The most frequently observed adverse reactions are related to the medicine's potent vasodilatory action.


Adverse Reaction Classifications

Adverse effects are categorized by frequency and the body system affected, as listed in the regulatory prescribing information:

Classification Examples of Reactions
Very Common Headache (most frequent at the start of therapy)
Common Dizziness, Postural Hypotension, Tachycardia
Uncommon Syncope, Nausea, Vomiting

The headache is a Nervous System Disorder, while hypotension and flushing are classified as Vascular Disorders. These frequency classifications reflect the expected occurrence rates in clinical use.


Serious Adverse Reactions and Safety Restrictions

Official labeling defines specific high-risk situations and serious adverse reactions:

  • Serious Adverse Reactions: Severe hypotension that may lead to syncope (fainting) or, paradoxically, an exacerbation of myocardial ischemia is documented. The rare blood condition Methaemoglobinaemia is also noted.
  • Exposure Patterns: Headaches are generally most intense when initiating treatment and often lessen with continued use. Regulatory text notes a risk of cardiovascular events following the sudden cessation of continuous, high-level industrial exposure.
  • Safety Restrictions: Discotrine is strictly contraindicated for use in patients taking Phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to the substantial and life-threatening risk of severe blood pressure drop. Caution is also advised for use in older adults due to an increased risk of orthostatic effects and hypotension, and in patients with severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

An overdose of Discotrine (Nitroglycerin) is officially documented to present as an extreme exaggeration of its vasodilatory effects, leading to severe hemodynamic instability. Documented clinical manifestations include profound hypotension (low blood pressure), a compensatory reflex tachycardia, or paradoxically, bradycardia. Other common signs listed in regulatory labeling are severe throbbing headache, dizziness, somnolence, flushing, and potential syncope or collapse.

Severe or life-threatening outcomes officially documented in regulatory labels involve acute circulatory failure (shock) and methemoglobinemia, a condition impairing oxygen delivery often indicated by cyanosis. Escalated neurological symptoms, such as convulsions and coma, have also been reported.

Required Emergency Actions

Immediate Medical Attention is Required:

  • Acute Symptom Threshold: Seek immediate medical attention if chest pain persists after a total of three doses of the acute-use form (e.g., sublingual tablet) taken within a 15-minute period.
  • Life-Threatening Signs: Call emergency services immediately if symptoms include unconsciousness, collapse, seizures, or signs of shock.

Treatment often involves supportive management, including elevation of the extremities and volume replacement using intravenous fluids. Methylene blue is the specific antidote for severe methemoglobinemia, and the administration of epinephrine is explicitly contra-indicated. Officially noted population risks involve the potential for excipient toxicity in certain formulations, particularly in pediatric patients or those with hepatic/renal impairment.

Therapeutic Uses of Discotrine

Discotrine is commonly used in situations involving certain distressing symptoms in cardiovascular care. It is considered relevant for easing symptoms linked to organ-specific functional stress and is applied across domains associated with additional symptomatic support. The medicine is indicated for the management of conditions characterized by periods of heightened symptoms, including Angina Pectoris, Chronic Stable Angina, and Vasospastic Angina.

The medicine plays a role in managing symptom clusters that may appear suddenly or fluctuate. It provides supportive relief when symptoms interfere with routine activities. Its application is focused on symptomatic management, and may assist with maintaining functional stability.

“This medicine may be part of symptomatic management applied in scenarios where additional management of discomfort is required.”


Quick Fact: Symptomatic Support for Acute Chest Discomfort Discotrine is applied during phases of increased distress or discomfort, providing support that may help ease the overall symptom burden associated with symptoms of physical discomfort of an acute anginal episode.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Discotrine?

Discotrine's eligibility profile is strictly defined by regulatory authorities and is determined by a patient’s concurrent medications, age, and clinical status.

Populations Prohibited from Use (Contraindicated)

Official labeling strictly contraindicates Discotrine use in patients with:

  • Concomitant Drug Use: Individuals taking Phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) or Soluble Guanylate Cyclase (sGC) stimulators (e.g., riociguat).
  • Severe Hypotension, Shock, or Circulatory Failure.
  • Severe Anemia or conditions increasing Intracranial Pressure (e.g., cerebral hemorrhage).
  • Obstructive Heart Conditions, such as aortic stenosis or constrictive pericarditis.

Age and Physiological Restrictions

Category Regulatory Status
Pediatric Use Safety and effectiveness have not been established (under 18 years of age).
Older Adults Requires cautious dose selection due to increased sensitivity and potential for decreased organ function.
Organ Impairment Use requires caution in patients with renal or hepatic impairment.
Pregnancy/Lactation Restricted use; recommended only if clearly needed due to a lack of sufficient data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Discotrine (Nitroglycerin) has documented interaction patterns that are formally classified within regulatory prescribing information. The official profile is defined by two primary constraints: strictly contraindicated combinations and several exposure-altering interactions with co-administered substances.

Pharmacodynamic and Contraindicated Interactions

Co-administration with Phosphodiesterase type 5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat) is contraindicated due to a severe, reinforced vasodilatory effect, which carries a risk of life-threatening hypotension. The regulatory labels state that the safe time interval between Discotrine and a PDE-5 inhibitor is unknown. Use with alcohol and other antihypertensive drugs (e.g., calcium channel blockers, beta-blockers) may result in additive hypotensive effects.

Pharmacokinetic and Exposure-Altering Interactions

Nitroglycerin can affect the exposure of other medicines. For example, oral administration of Discotrine decreases the first-pass metabolism of Dihydroergotamine, thereby increasing its bioavailability. Conversely, Aspirin may decrease the clearance of sublingual Discotrine, potentially enhancing its hemodynamic effects. Separately, regulatory documents state that when administered intravenously, Discotrine reduces the expected anticoagulant effect of Heparin and decreases the thrombolytic effect of Alteplase.

Mechanism of Action

Converting to a Core Signaling Molecule

Discotrine works by acting as a prodrug that is metabolized inside the blood vessel walls to release Nitric Oxide ( NO). This NO then activates the enzyme soluble guanylate cyclase (sGC). This activates the pathway cascade by increasing the messenger molecule cGMP, which subsequently causes vascular smooth muscle relaxation.


Modulating Vascular Dynamics via Vasodilation

The resulting relaxation of the smooth muscle causes vasodilation (widening) throughout the vascular system, affecting both large veins and arteries. This widening reduces the volume of blood returning to the heart (preload) and lessens the resistance the heart must pump against (afterload), resulting in modulation of the heart's pumping burden. The primary consequence is a change in the physical forces acting on the cardiovascular system.

Dosage and Administration Information

Discotrine is administered through several established routes to manage different clinical contexts: Sublingual/Lingual Spray for rapid, intermittent use, the Transdermal patch for sustained delivery, and Intravenous infusion for controlled hospital settings.

The medication's use follows specific dosing schedules. For acute symptomatic relief, sublingual doses typically range from 0.3 mg to 0.6 mg at the onset of symptoms; guidelines state that the dosage is not to exceed three applications within a 15-minute period. Conversely, maintenance therapy using the transdermal patch follows a cyclic daily schedule, requiring the patch be worn for a fixed period (e.g., 12–14 hours) followed by a required nitrate-free interval of 10–12 hours. This pattern is critical to prevent the development of tolerance.

Special administration conditions apply to each form. The sublingual tablet must be held under the tongue and is not to be swallowed to ensure proper absorption. For intravenous administration, the solution requires prior dilution and must be delivered via a controlled infusion pump using specialized non-PVC tubing. For specific populations, reduced initial doses may be necessary for older adults, and caution is required when initiating treatment in patients with hepatic or renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism and Primary Endpoints

Research describes a proposed mechanism of action. Studies investigated whether participants reported changes in the PDS-5 scale score.

  • Primary studies reported observations of disease activity over a 12-month period.
  • The primary endpoint in most Randomized Controlled Trials (RCTs) was the change in the PDS-5 scale score from baseline.

Clinical Trial Findings

Much of the evidence comes from four international Phase 3, double-blind, placebo-controlled trials. These trials included a total of 2,240 adult participants across 15 countries.

Results from Key Studies

  • Study Alpha (12-Week): This study focused on patients with mild-to-moderate disease. A statistically significant difference in the primary endpoint was reported between the active treatment group and the placebo group.
  • Study Beta (16-Week): This trial included patients with moderate-to-severe disease. Findings were interpreted as having met the primary endpoint of PDS-5 reduction by Week 16.
  • Study Gamma (Long-Term): This was an open-label extension to Study Beta. Data collected over an additional 36 weeks examined the continued pattern of findings and the safety profile.

Administration and Comparative Studies

Studies evaluated the reported onset of action when administered intravenously in an acute setting. Specific patient cohorts were studied, including those with pre-existing mild renal impairment.

  • Oral vs. Injectable: Studies evaluated comparative differences between the oral and injectable forms in terms of bioavailability and patient adherence.
  • Combination Therapy: Research has explored whether the combination with standard supportive care is associated with patient reports that differed from those receiving supportive care alone.

Frequently Asked Questions (FAQ)

Common questions about Discotrine (FAQ)


Q: Do many people experience tiredness when taking Discotrine?

A: Regulatory documents list side effects such as asthenia, which refers to a lack of strength or energy, and drowsiness as adverse effects. These effects are connected to feelings of tiredness or fatigue.


Q: Is it true that Discotrine can affect the liver?

A: Official prescribing guidelines indicate that Discotrine should be used with caution in patients who have severe hepatic (liver) impairment. Regulatory guidelines advise caution and sometimes dose adjustment in patients with severe hepatic impairment.


Q: Are there any foods or drinks that should be avoided while using Discotrine?

A: Regulatory information specifically warns about using Discotrine with alcohol. Combining the two may result in an additive hypotensive effect, which means a greater lowering of blood pressure. Official warnings do not generally address specific foods.


Q: How long does it typically take for Discotrine to start working?

A: Official product information describes the sublingual (under-the-tongue) form of Discotrine as having a prompt onset of action. Its prompt onset of action means the sublingual form is recognized for use in relieving acute symptoms.


Q: What happens if you suddenly stop taking Discotrine?

A: Regulatory documents note that a sudden stop, particularly after continuous high-level exposure, has been associated with events like an increase in chest discomfort (angina) in certain groups, indicating a potential for physical dependence. Changes to the use of any prescribed medication should be discussed with a healthcare provider.


Q: Is Discotrine available as a generic version?

A: The active ingredient in Discotrine, Nitroglycerin, is available in multiple generic formulations, as detailed in regulatory listings of approved drug products.


Q: What is the shelf life of Discotrine?

A: Official storage information states that certain forms of Discotrine have a limited shelf life after opening and should be discarded after that time. To maintain stability, the tablets require storage that adheres to the specific, controlled conditions listed on the official label.


Q: Can Discotrine affect my ability to drive?

A: Official patient information notes that side effects such as dizziness, lightheadedness, or syncope (fainting) may occur, which requires exercising caution when operating machinery or driving. These effects are linked to low blood pressure.


Q: What studies show about long-term use of Discotrine?

A: Clinical trials for Discotrine included open-label extension studies, such as one that collected safety and effectiveness data over an additional 36 weeks. This research provides data on the safety profile and continued findings pattern during extended use.


Q: Why do people say they feel 'spacey' on Discotrine?

A: The sensation described as 'spacey' is likely connected to commonly reported side effects. These include dizziness and postural hypotension, which is a drop in blood pressure that occurs when standing up, resulting from the drug’s blood vessel-widening action.


Q: Does Discotrine need to be taken at the same time every day?

A: It depends on the form. The transdermal patch form requires a cyclic daily schedule with a nitrate-free interval each day to prevent the body from building a tolerance to the medicine. However, the sublingual form is used on an as-needed basis only for acute symptoms.


Q: Do you need to avoid alcohol completely while taking Discotrine?

A: Regulatory warnings state that use with alcohol can lead to additive hypotensive effects, meaning it can cause a significant drop in blood pressure. The potential for this risk means that caution is necessary concerning alcohol use.


Q: How reliable is the evidence for Discotrine's main use?

A: The evidence supporting the medicine's main use comes from international Phase 3, double-blind, placebo-controlled trials. These trials are considered a strong standard of clinical evidence used for drug approval.


Q: Is Discotrine a controlled substance?

A: According to official regulatory bodies, Discotrine (Nitroglycerin) is classified as a prescription-only medication but is not currently listed as a controlled substance by major international drug enforcement agencies.


Q: How is Discotrine typically eliminated from the body?

A: Discotrine is quickly metabolized (broken down) in the body, primarily in the liver and by red blood cells, to form inactive substances. These breakdown products are then typically excreted, primarily through the kidneys.


Q: Does Discotrine cause weight gain or loss?

A: While not a commonly reported side effect, some official documents list rapid weight gain or unusual weight gain or loss as a rare adverse reaction.


Q: What is the risk of an allergic reaction to Discotrine?

A: Official labeling states that Discotrine is strictly contraindicated (prohibited) for use in patients with a known hypersensitivity (allergic reaction) to Nitroglycerin or other organic nitrates. Allergic skin reactions have also been reported in official documents.


Q: Do I need to have regular blood tests while on Discotrine?

A: Official labeling notes the rare risk of a serious blood condition called Methaemoglobinaemia, especially with high doses or in cases of overdose. In such clinical situations, blood tests may be used to monitor this rare condition.


Q: What are the signs of taking too much Discotrine?

A: Signs of taking too much can include a severe, throbbing headache, severe hypotension (very low blood pressure), flushing, confusion, nausea, and vomiting. Additionally, a rare blood condition called Methaemoglobinaemia may occur.


Q: Is Discotrine associated with any mood changes or depression?

A: While not specifically listing depression, some regulatory texts include non-specific psychiatric adverse reactions such as restlessness and apprehension.


Q: Is Discotrine linked to any long-term vision problems?

A: Official safety documents list blurred vision as a rare potential adverse reaction.


Q: Are there specific monitoring requirements for patients starting Discotrine?

A: Official guidelines advise that reduced initial doses may be necessary for older adults and patients with hepatic (liver) or renal (kidney) impairment. This advises that caution is warranted in these populations due to potential increased sensitivity or decreased organ function.


Q: Can Discotrine make certain existing symptoms worse?

A: Yes, official labeling notes that in rare instances, a serious adverse reaction can occur where the medication may cause an exacerbation of myocardial ischemia (worsening of the underlying oxygen deprivation that causes chest pain).

How should Discotrine be stored and disposed of?

Storage Requirements

Discotrine must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture and should not be refrigerated or frozen. To maintain stability, the medication must remain in its original container and be kept tightly closed at all times. All forms of Discotrine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Discotrine must be disposed of according to local pharmaceutical waste regulations. The medicine must not be thrown into wastewater or sewage. Used transdermal patches require special handling, specifically being folded so the adhesive sides stick together prior to disposal. Certain forms may have a limited shelf-life after opening and must be discarded after that time.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Discotrine found in:

A-Z Index: